Loading...
Home 2017-04-13T01:43:52+00:00

What do we do?

Our work allows cancer drugs to be efficiently produced, and delivered to cancerous tumors in a targeted fashion that doesn’t destroy the patient’s normal healthy cells indiscriminantly. We do this by simplifying and standardizing the production of antibody drug conjugates to treat cancer, using proprietary site-selective chemistries as protein modification technologies.

Who are we?

We are established scientists and medical professionals determined to treat people around world with superior, targeted cancer therapeutics.

Partnership opportunities

Leverage our novel chemistries to create your superior targeted therapeutics to treat cancer.

Investment opportunities

We have two parallel development paths: platform technology with the ability to be licensed by others and our own proprietary therapeutic products to treat cancer

Latest News and Events

ADVANCED PROTEOME THERAPEUTICS AND IMMUNOBIOCHEM CORPORATION ENTER INTO A COLLABORTATION AND OPTION AGREEMENT

Feb 7, 2018 (Vancouver, BC and Toronto, ON): Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, today announced entering into a Collaboration and Option agreement to develop superior antibody-drug conjugates.  The companies will evaluate the prospect of combining ImmunoBiochem’s proprietary antibody and APC’s site-selective [...]

February 17th, 2018|

We just moved into JLABS@Toronto

Advanced Proteome Therapeutics Corporation has offices in Canada at JLABS@Toronto and in Boston.